A Phase 1b, Open-Label, Safety and Tolerability Study of TTAC-0001 in Combination With Pembrolizumab in Patients With Recurrent Glioblastoma
Phase of Trial: Phase I
Latest Information Update: 30 Jan 2019
At a glance
- Drugs Pembrolizumab (Primary) ; Tanibirumab (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors PharmAbcine
- 17 Jan 2019 Status changed from not yet recruiting to recruiting.
- 02 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 3 Jan 2019.
- 12 Dec 2018 According to a PharmAbcine media release, the company has completed the preparations to launch this combination study in Australia.